Abivax SA

Sofinnova Crossover I SLP and associated individuals have amended their Schedule 13D filing to report the sale of Abivax S.A. American Depositary Shares and Ordinary Shares.

Sofinnova Crossover I SLP and associated parties have filed an amendment to their Schedule 13D, disclosing changes in beneficial ownership and a transaction involving royalty certificates.

Sofinnova Crossover I SLP and related entities have reduced their beneficial ownership in Abivax S.A. by selling approximately 1 million American Depositary Shares (ADS) across two days in January 2026.

Sofinnova Crossover I SLP and related entities have reduced their beneficial ownership in Abivax SA to approximately 5.6% of outstanding ordinary shares through recent ADS sales.

Sofinnova Crossover I SLP and its affiliates have increased their beneficial ownership in Abivax SA to 11.4% of voting rights through a $17.28 million acquisition of American Depositary Shares in a recent public offering.

Sofinnova Crossover I SLP and its affiliates have increased their voting rights in Abivax SA to 11.0% due to the automatic application of French double voting rights for long-held shares.

TCG Crossover entities have filed an amendment to their Schedule 13G, reporting a combined beneficial ownership of 7.0% in Abivax SA ordinary shares following a recent offering.

Several entities affiliated with Invus Group and Raymond Debbane have collectively acquired a 6.0% stake in Abivax S.A., signaling a notable investment in the biopharmaceutical company.

Invus Public Equities and related entities have reported a 5.0% beneficial ownership stake in Abivax S.A., totaling 3,922,995 ordinary shares.

A group of Venrock entities and individuals have filed an amendment to their Schedule 13G, disclosing a beneficial ownership of 0.8% of Abivax SA's ordinary shares as of September 30, 2025.

TCG Crossover Fund I, L.P., TCG Crossover Fund II, L.P., and their related entities, along with Chen Yu, have disclosed a combined beneficial ownership of 9.1% in Abivax SA as of September 30, 2025.

Deep Track Capital, LP and affiliated entities have updated their beneficial ownership in Abivax SA to 4.78% of outstanding Ordinary Shares.